| Literature DB >> 3802114 |
M R O'Donnell, S J Forman, A M Levine, M Territo, M J Farbstein, J L Fahey, P Gill, G Lazar, A Nademanee, S Neely.
Abstract
A phase II trial of cytarabine, cisplatin, and etoposide was conducted in 38 patients with refractory stage III and IV non-Hodgkin's lymphoma. There were two complete and nine partial responses (32%) among 35 evaluable patients. Response rate in patients with large cell lymphoma was 45%. The dose-limiting toxic effect was myelosuppression in 66% of patients.Entities:
Mesh：
Substances：
Year: 1987 PMID： 3802114
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960